OQS
CUE icon

Occudo Quantitative Strategies’s Cue Biopharma CUE Stock Holding History

Occudo Quantitative Strategies’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-969
Closed -$55K – 794
2024
Q1 		$55K Sell
969
-146
-13% -$10.3K 0.01% 690
2023
Q4 		$88.3K Buy
+1,115
New +$79.7K 0.01% 716
2023
Q3 		– Sell
-1,259
Closed -$138K – 1036
2023
Q2 		$138K Buy
1,259
+821
+187% +$96.5K 0.01% 898
2023
Q1 		$46.9K Sell
438
-51
-10% -$4.86K ﹤0.01% 851
2022
Q4 		$41.8K Sell
489
-184
-27% -$16.8K ﹤0.01% 889
2022
Q3 		$45K Sell
673
-1,532
-69% -$132K ﹤0.01% 1102
2022
Q2 		$165K Buy
2,205
+406
+23% +$47.5K 0.01% 953
2022
Q1 		$263K Buy
+1,799
New +$381K 0.02% 862

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Occudo Quantitative Strategies's CUE Position: Q2 2024 in Review

Occudo Quantitative Strategies sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 969 shares — an estimated $55K sold.

Occudo Quantitative Strategies first reported a position in CUE in Q1 2022 and held it in 8 quarters. The position peaked at $263K in Q1 2022. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Occudo Quantitative Strategies reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 969 Cue Biopharma shares in Q2 2024, an estimated $55K.
  • Occudo Quantitative Strategies first reported a position in Cue Biopharma in Q1 2022 and held it in 8 quarters.
  • Occudo Quantitative Strategies's Cue Biopharma position peaked at $263K in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.